1. Volume 385, Issue 9980, Pages 1873-1883 (May 2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial 
Prof Peter Hillmen, MB ChB, Tadeusz Robak, MD, Ann Janssens, MD, K Govind Babu, MD, Janusz Kloczko, MD, Sebastian Grosicki, MD, Michael Doubek, MD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Andrew R Pettitt, MRCPath, Thomas Boyd, MD, Marco Montillo, MD, Ira V Gupta, MD, Oliver Wright, BSc, Iestyn Dixon, BSc, Jodi L Carey, RN BSN, Chai-Ni Chang, MS, Steen Lisby, MD, Astrid McKeown, PhD, Fritz Offner, MD 
The Lancet 
Volume 385, Issue 9980, Pages (May 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Study profile
ITT=intention to treat. *Includes death during treatment (n=5 for both groups). †Includes one patient who had protocol deviation.
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Progression-free survival (A) and overall survival (B) by treatment group
Progression-free survival was defined as the time between randomisation and the date of disease progression or death from any cause; data were censored for patients with two or more missing visits or start of alternative treatment before progression or death. Overall survival was defined as time between randomisation and date of death; patients who had not died by the analysis data cutoff date were censored at their last contact date. HR=hazard ratio.
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Treatment effect on progression-free survival in prognostic subgroups
HR=hazard ratio.
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions